1. REBACIN® is an optional intervention for persistent high-risk human papillomavirus infection: A retrospective analysis of 364 patients
- Author
-
E. Yang, Xiu Ming, Ying Yang, Tingwenyi Hu, Zhengyu Li, and Wenjiao Min
- Subjects
Adult ,medicine.medical_specialty ,Cytodiagnosis ,Uterine Cervical Neoplasms ,Antiviral Agents ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Cytology ,Intervention (counseling) ,Internal medicine ,Retrospective analysis ,medicine ,Humans ,030212 general & internal medicine ,Human papillomavirus ,Papillomaviridae ,Aged ,Retrospective Studies ,Cervical cancer ,Biological Products ,030219 obstetrics & reproductive medicine ,Hpv types ,business.industry ,Papillomavirus Infections ,Obstetrics and Gynecology ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,Confidence interval ,Treatment Outcome ,Female ,business - Abstract
Objective To evaluate the therapeutic efficacy of REBACIN® in patients with persistent high‐risk HPV (hrHPV) infection. Persistent hrHPV infection is a crucial cause of cervical cancer, for which optimal pharmacological intervention remains unavailable. Methods A retrospective analysis and a meta‐analysis were carried out. The retrospective analysis included 364 patients who were persistently infected with HPV for at least 12 months, between September 2015 and February 2019, and only received the REBACIN® intervention. HPV DNA typing, HC2 hrHPV DNA, and ThinPrep cytologic tests were performed before and after the REBACIN® intervention, to evaluate the therapeutic efficacy. The meta‐analysis included trials evaluating the therapeutic efficacy of interferons. Results After a follow‐up period of 3–6 months, the overall rate of efficacy of REBACIN® was 74.73% (272/364), which was higher than that of interferon (61.50%). The efficacy of REBACIN® was correlated with HPV type (odds ratio [OR] 0.549, 95% confidence interval [CI] 0.367–0.822, P=0.004) and pretreatment cytology (OR 0.358, 95% CI 0.173–0.739, P=0.005). Conclusion REBACIN® is potently efficacious at clearing persistent hrHPV infection; hence, it can serve as an optional intervention for persistent hrHPV infection.
- Published
- 2020